STAGE
BY GRADIENCE HEALTH™
Gradience Health

MRI physics, translated into measurements clinicians can act on.

Gradience Health — formerly SpinTech MRI — builds quantitative imaging technology that turns a single MRI acquisition into standardized, physics-based maps of tissue.

Our FDA cleared platform, STAGE, is deployed on existing 1.5T and 3T scanners, and our science originates from more than two decades of susceptibility-based MRI research and is utilized by clinicians across the US.

Clinician reviewing quantitative brain MRI maps across multiple monitors
OUR ORIGIN

Two decades of MRI research, built into a platform.

The company was founded to commercialize susceptibility-weighted and quantitative susceptibility imaging methods developed over decades of academic MRI research — work that put SWI and QSM into routine neuroimaging worldwide.

We became Gradience Health to reflect what the company is now: a gradient echo-based quantitative imaging software platform, with STAGE as its first clinical product.

LEADERSHIP

The people behind the platform

A team that combines deep imaging expertise with a strong track record of scaling medtech.

Brian Martin
CHIEF EXECUTIVE OFFICER
Brian brings more than twenty years in medtech — most recently scaling the neuro-technology company GT Medical from pre-FDA to a $30M revenue run rate — with earlier work spanning venture investing, a life sciences incubator and device marketing.
John Ciliberto
VP OF CLINICAL APPLICATIONS
John has spent 25+ years in radiology and diagnostic imaging commercial leadership, including VP positions at Radiology Partners and Foundation Radiology, and roles at QMENTA, Nines and icometrix.
Paul Kokeny
VP OF TECHNOLOGY
Paul has 15+ years in MRI physics technology development. He leads the research and software teams that make STAGE outputs reproducible across scanners and sites. Paul holds a PhD in Biomedical Engineering from Wayne State University, where his research focused on quantitative MRI.